EUCTR2005-000359-13-HU进行中（未招募）1 期
Hungarian Study of Maintenance after Rituximab Pretreatment. A multicentre, phase III, open-label study evaluating the benefit of a long-term MabThera® (rituximab) maintenance therapy in patients with advanced follicular lymphoma after induction of response (CR(u) or PR) with a MabThera® (rituximab)-containing first line regimen - HUSOM
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 124
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •a.Signed an IRB- approved written informed consent.
- •b.Histologically confirmed follicular lymphoma grade 1, 2, or 3a (see Appendix C) with a lymph node biopsy performed within 4 months before the induction treatment and with material available for eventual further review
- •c.Documented parameters for FLIPI determination (Appendix I) before induction therapy
- •d.No previous antilymphoma treatment received before the induction chemotherapy. (Just first line treated patients are eligible.)
- •e.Verified complete or partial remission (CR(u) or PR) (see Appendix A) after induction (Allowed induction treatments are listed in Appendix B). Staging (see Appendix C) must be started 4 weeks after the last MabThera® infusion in the induction scheme and must be completed 2 weeks before baseline. The maximum allowed period between the last infusion of the induction and first infusion of MabThera® maintenance therapy is 8 weeks. Eligible first line induction regimens before staging (Appendix B):
- •i.MabThera® plus CVP chemotherapy (R-CVP), containing 8 cycles of CVP given together with 8 cycles of MabThera®
- •ii.MabThera® plus CHOP chemotherapy (R-CHOP), containing 6-8 cycles of CHOP given together with 8 cycles of MabThera®.
- •iii.2 cycle of R-CVP followed by 6 cycle of R-CHOP. If the treatment of patient started by R-CVP, and the response after 2 cycle of R-CVP was unsatisfactory by the judgement of physician, the treatment can be continued by 6 cycles of R-CHOP
- •f.Males or females, older than 18 years
- •g.Expected survival > 4 months.
- •h.Prestudy performance status ECOG 0, 1 or 2 (see Appendix D)
- •i.Acceptable hematological status within two weeks prior to treatment start, including:
- •I.Hb > 8.0 g/dL.
- •II.WBC > 3.0 x 103/ mm3 (x 109/ L).
- •III.Absolute granulocyte count (segmented neutrophils + bands x total WBC) >1.5 x 103/ mm3 (x 109/ L).
- •IV.Platelet count >75 x 103/ mm3 (x 109/ L).
- •j.Women must agree to follow accepted birth control methods during the trial. In case of men also an agreement for contraception is needed until the end of the first year after receiving the last infusion of maintenance treatment.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •a.Grade 3b follicular lymphoma
- •b.Any previous antilymphoma treatment before induction chemotherapy. (Relapsed patients)
- •c.Patients received other induction pretreatment as specified in Appendix B
- •d.Transformation to high grade lymphoma (except to grade 3a) of the previously existed follicular lymphoma
- •e.Presence of CNS lymphoma.
- •f.AIDS-related lymphoma.
- •g.Active opportunistic or known HIV, HBV or HCV infection.
- •h.Major surgery, other than diagnostic surgery, within 4 weeks prior to registration.
- •i.Another primary malignancy (other than squamous cell carcinoma of the skin or in situ carcinoma of the cervix) for which the patient has not been disease-free for at least five years.
- •j.Patients with abnormal liver function unless directly related to hepatic involvement by lymphoma.
- •I.Total bilirubin >2.0 mg/d L (35 µmol/L).
- •II.Alkaline phosphatase >3 x upper limit of normal range.
- •III.AST (SGOT) >3 x upper limit of normal range.
- •k.Patients with abnormal renal function (serum creatinine >2.0 mg/d L [177 µmol/L]).
- •l.New York Heart Association Class III or IV heart disease (see Appendix E) or myocardial infarction within the past 6 months.
- •m.Patients regularly taking corticosteroids during the last 4 weeks, unless administered at a dose equivalent to <20 mg/day prednisone for indications other than lymphoma or lymphoma-related symptoms.
- •n.Serious underlying medical conditions, which could impair the ability of the patient to participate in the trial (e.g. active uncontrolled bacterial, viral, or fungal ongoing infection(s), hydronephrosis, uncontrolled diabetes mellitus, uncontrolled gastric ulcers, active autoimmune disease). Judgment is up to the investigator.
- •o.Sensitivity or allergy to murine products
- •p.Treatment within a clinical trial within 30 days prior to trial entry.
- •q.Female patients who are pregnant or lactating.
研究者
相似试验
进行中（未招募）
不适用
Efficacy of maintenance therapy with rituximab after induction chemotherapy (R-CHOP vs R-FC) for elderly patients with mantle cell lymphoma not suitable for autologous stem cell transplantation - MCL elderlyMantle cell lymphomaEUCTR2005-005375-15-BEGELA570
进行中（未招募）
1 期
Evaluation of Rituximab-based Regimen Compared to Conventional Therapeutic Strategy For Remission Induction In Patients With Newly-Diagnosed or Relapsing Eosinophilic Granulomatosis With Polyangiitis. Prospective, randomized, controlled, double-blind study. - REOVASEUCTR2016-000275-25-FRASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)108
进行中（未招募）
不适用
Rituximab-2cda + Rituximab maintenance in Chronic Lymphocytic Leukaemia and Small Lymphocytic Lymphoma - NDEUCTR2010-018519-14-ITISTITUTO EUROPEO DI ONCOLOGIA
已完成
3 期
Rituximab Versus Observation as Maintenance Therapy in Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia)Chronic Lymphocytic LeukemiaNCT01118234Arbeitsgemeinschaft medikamentoese Tumortherapie256
已完成
不适用
Phase II study of Rituximab in Patients with Systemic Lupus ErythematosusSystemic lupus erythematosusJPRN-UMIN000000762Zenyaku Kogyo Co., Ltd.70